Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022.

ABSTRACT:

Background and aims

Extended release buprenorphine injection (INJ-BUP) has been available in the United States since 2018. INJ-BUP has the potential to positively impact opioid use disorder (OUD) treatment outcomes by providing additional treatment options. As one of the largest payers of OUD treatment in the US, Medicaid coverage is important for access and uptake of INJ-BUP. Uptake of INJ-BUP among Medicaid beneficiaries has not been described since 2019 and variation in uptake by state has not previously been explored. We aimed to measure prescribing of INJ-BUP for Medicaid beneficiaries since 2018, nationwide and by state.

Methods

We analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ-BUP and oral buprenorphine p

SUBMITTER: Ross RK 

PROVIDER: S-EPMC12050076 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature